Conference Correspondent

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Phoebe Starr

October 2019, Vol 10, No 5 - ESMO 2019

Barcelona, Spain—Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-­positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting. [ Read More ]

Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Pancreatic Cancer

Orlando, FL—Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the updated National Comprehensive Cancer Network (NCCN) guideline for pancreatic cancer presented at the 2019 NCCN Conference. [ Read More ]

New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Colorectal Cancer

Orlando, FL—A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline. [ Read More ]

Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference

Orlando, FL—Maintaining patient safety and minimizing the risks for opioid misuse and abuse in the management of cancer pain require proper assessment and new strategies for pain management that include integrative interventions, according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago. She discussed this topic at the 2019 National Comprehensive Cancer Network (NCCN) Conference. [ Read More ]

Expert Panel Discusses Access to CAR T-Cell Therapy

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference

Orlando, FL—With price tags approaching $1 million or more for delivery of certain immune cell therapies, new payment models will be needed to ensure access to these therapies and to further innovations. This was a key issue addressed at a roundtable discussion at the 2019 National Comprehensive Cancer Network (NCCN) Conference. Ensuring access to chimeric antigen receptor (CAR) T-cell therapy emerged as a top area of concern. [ Read More ]

SM-88, a Novel Tumor Metabolism–Altering Regimen, Shows Promise as Third-Line Therapy for Metastatic Pancreatic Cancer

Wayne Kuznar

April 2019, Vol 10, No 2 - GI Cancers Symposium

San Francisco, CA—Increased understanding of tumor genetics and tumor metabolism has led to improved therapies for cancer. The impact of cancer metabolism on tumor pathways is particularly important in pancreatic cancer. A novel tumor metabolism–altering oral drug known as SM-88 combines the investigative tyrosine derivative (D,L-alpha-metyrosine) with 3 repurposed agents—an mTOR inhibitor (sirolimus), a CYP3A4 inducer (phenyt­oin), and an oxidative stress catalyst (methoxsalen). [ Read More ]

Triple-Drug Regimen Improves Survival in Metastatic Colorectal Cancer with BRAF V600E Mutation

Wayne Kuznar

April 2019, Vol 10, No 2 - GI Cancers Symposium

San Francisco, CA—Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib (Braftovi), a BRAF inhibitor; binimetinib (Mektovi), a MEK inhibitor; and cetuximab (Erbitux), an EGFR inhibitor, for the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation. [ Read More ]

Pembrolizumab a Promising Second-Line Option in PD-L1 Expressing Advanced Esophageal Cancer

Wayne Kuznar

April 2019, Vol 10, No 2 - GI Cancers Symposium

San Francisco, CA—Pembrolizumab (Keytruda) as a second-line therapy improved overall survival (OS) in patients with advanced or metastatic esophageal cancer and high PD-L1 expression compared with chemotherapy, according to findings from the phase 3 KEYNOTE-­­­181 study presented at the 2019 Gastrointestinal Cancers Symposium. [ Read More ]

Adjuvant Therapy with Durvalumab Shows Promise in Advanced Esophageal Cancer

Wayne Kuznar

April 2019, Vol 10, No 2 - GI Cancers Symposium

San Francisco, CA—Adjuvant treatment with durvalumab (Imfinzi), a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adeno­carcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial. Historically, the 1-year relapse rate has been 50% in patients with GEJ carcinoma who do not achieve a pathologic complete response with trimodal therapy, even with additional chemotherapy, said Hirva Mamdani, MD, Thoracic Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, at the 2019 Gastrointestinal Cancers Symposium. [ Read More ]